Acetaminophen Use During Pregnancy Not Linked to Neurodevelopmental Disorders
By Elana Gotkine HealthDay Reporter
THURSDAY, April 11, 2024 -- In sibling control analyses, acetaminophen use during pregnancy was not associated with children's risk for autism, attention-deficit/hyperactivity disorder (ADHD), or intellectual disability, according to a study published online in the April 9 issue of the Journal of the American Medical Association.
Viktor H. Ahlqvist, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a nationwide cohort study with a sibling control analysis including a population-based sample of 2,480,797 children born in 1995 to 2019 in Sweden to examine the associations of acetaminophen use during pregnancy with children's risk for autism, ADHD, and intellectual disability.
The researchers found that ever-use versus no use of acetaminophen during pregnancy was associated with a marginally increased risk for autism (hazard ratio, 1.05; 95 percent confidence interval, 1.02 to 1.08), ADHD (hazard ratio, 1.07; 95 percent confidence interval, 1.05 to 1.10), and intellectual disability (hazard ratio, 1.05; 95 percent confidence interval, 1.00 to 1.10) in models without sibling control. Matched full-sibling pairs were also analyzed to address unobserved confounding. There was no evidence that acetaminophen use during pregnancy was associated with autism, ADHD, or intellectual disability in sibling control analyses. No evidence of a dose-response pattern was seen in sibling control analyses.
"This suggests that associations observed in models without sibling control may have been attributable to confounding," the authors write.
One author disclosed ties to Neobiomics AB; a second author disclosed ties to law firms and AlphaSights.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental...
New Neurocognitive/Functional Morbidity Explored in SARS-CoV-2, MIS-C
WEDNESDAY, June 12, 2024 -- Children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome in children (MIS-C) with severe...
FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.